<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109306</article-id><article-id pub-id-type="publisher-id">ACM-37710</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_98512481.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  塞来昔布联合玻璃酸钠治疗膝骨关节病疗效探究
  The Effect of Celecoxib Combined with Sodium Hyaluronate in the Treatment of Knee Osteoarthropathy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>旋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>史</surname><given-names>为鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>奎帅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>沈</surname><given-names>瑞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2042</fpage><lpage>2047</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：通过比较塞来昔布、塞来昔布联合玻璃酸钠治疗膝骨关节病的疗效，为临床治疗提供参考。方法：选取2019年1月至6月于我院接受保守治疗的膝骨关节病患者100例，按照随机数法分为单纯口服塞来昔布组和塞来昔布联合玻璃酸钠组各50例，塞来昔布200 mg，2次/日，连续口服8周；玻璃酸钠注射液2.5 ml，1次/周，5周为1疗程。随访患者接受治疗前、治疗后1个月、3个月、6个月的VAS疼痛评分、Lysholm评分及WOMAC评分。结果：两组患者治疗前VAS疼痛评分、Lysholm评分及WOMAC评分无明显差异(P &gt; 0.05)；治疗后1个月、3个月、6个月的VAS疼痛评分、Lysholm评分联合组均明显优于塞来昔布组，1个月、3个月的WOMAC评分联合组优于塞来昔布组(P &lt; 0.05)，6个月时两组差异无统计学意义(P &gt; 0.05)。结论：单纯口服塞来昔布、联合治疗均可取得良好的效果，但塞来昔布联合玻璃酸钠效果更佳，建议临床使用。
    Objective: To provide reference for clinical treatment by comparing the efficacy of celecoxib and celecoxib combined with sodium hyaluronate in the treatment of knee osteoarthritis. Method: A total of 100 patients with knee osteoarthritis who received conservative treatment in our hospital from January to June 2019 were randomly divided into oral celecoxib group (50) and celecoxib combined with sodium hyaluronate group (50); for example, celecoxib 200 mg, twice a day, orally for 8 consecutive weeks; sodium hyaluronate injection 2.5 ml, once a week, 5 weeks as a course of treatment. The VAS pain score, Lysholm score and WOMAC score were followed up before treatment, 1 month, 3 months, and 6 months after treatment. Results: There was no significant difference in VAS pain score, Lysholm score and WOMAC score between the two groups before treatment (P &gt; 0.05); the VAS pain score and Lysholm score in combined group were significantly better at 1 month, 3 months, and 6 months after treatment. In the celecoxib group, the combined WOMAC score of 1 month and 3 months was better than that of the celecoxib group (P &lt; 0.05), and there was no significant difference between the two groups at 6 months (P &gt; 0.05). Conclusion: Simple oral celecoxib and combination therapy can achieve good results, but the effect of celecoxib combined with sodium hyaluronate is better, and clinical use is recommended. 
  
 
</p></abstract><kwd-group><kwd>塞来昔布，玻璃酸钠，膝骨关节病，疗效, Celecoxib</kwd><kwd> Sodium Hyaluronate</kwd><kwd> Knee Osteoarthropathy</kwd><kwd> Curative Effect</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：通过比较塞来昔布、塞来昔布联合玻璃酸钠治疗膝骨关节病的疗效，为临床治疗提供参考。方法：选取2019年1月至6月于我院接受保守治疗的膝骨关节病患者100例，按照随机数法分为单纯口服塞来昔布组和塞来昔布联合玻璃酸钠组各50例，塞来昔布200 mg，2次/日，连续口服8周；玻璃酸钠注射液2.5 ml，1次/周，5周为1疗程。随访患者接受治疗前、治疗后1个月、3个月、6个月的VAS疼痛评分、Lysholm评分及WOMAC评分。结果：两组患者治疗前VAS疼痛评分、Lysholm评分及WOMAC评分无明显差异(P &gt; 0.05)；治疗后1个月、3个月、6个月的VAS疼痛评分、Lysholm评分联合组均明显优于塞来昔布组，1个月、3个月的WOMAC评分联合组优于塞来昔布组(P &lt; 0.05)，6个月时两组差异无统计学意义(P &gt; 0.05)。结论：单纯口服塞来昔布、联合治疗均可取得良好的效果，但塞来昔布联合玻璃酸钠效果更佳，建议临床使用。</p></sec><sec id="s2"><title>关键词</title><p>塞来昔布，玻璃酸钠，膝骨关节病，疗效</p></sec><sec id="s3"><title>The Effect of Celecoxib Combined with Sodium Hyaluronate in the Treatment of Knee Osteoarthropathy</title><p>Xuan Zhao, Weipeng Shi, Bin Yang, Kuishuai Xu, Rui Shen</p><p>Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/26-1571548x4_hanspub.png" /></p><p>Received: Aug. 30<sup>th</sup>, 2020; accepted: Sep. 14<sup>th</sup>, 2020; published: Sep. 21<sup>st</sup>, 2020</p><p><img src="//html.hanspub.org/file/26-1571548x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To provide reference for clinical treatment by comparing the efficacy of celecoxib and celecoxib combined with sodium hyaluronate in the treatment of knee osteoarthritis. Method: A total of 100 patients with knee osteoarthritis who received conservative treatment in our hospital from January to June 2019 were randomly divided into oral celecoxib group (50) and celecoxib combined with sodium hyaluronate group (50); for example, celecoxib 200 mg, twice a day, orally for 8 consecutive weeks; sodium hyaluronate injection 2.5 ml, once a week, 5 weeks as a course of treatment. The VAS pain score, Lysholm score and WOMAC score were followed up before treatment, 1 month, 3 months, and 6 months after treatment. Results: There was no significant difference in VAS pain score, Lysholm score and WOMAC score between the two groups before treatment (P &gt; 0.05); the VAS pain score and Lysholm score in combined group were significantly better at 1 month, 3 months, and 6 months after treatment. In the celecoxib group, the combined WOMAC score of 1 month and 3 months was better than that of the celecoxib group (P &lt; 0.05), and there was no significant difference between the two groups at 6 months (P &gt; 0.05). Conclusion: Simple oral celecoxib and combination therapy can achieve good results, but the effect of celecoxib combined with sodium hyaluronate is better, and clinical use is recommended.</p><p>Keywords:Celecoxib, Sodium Hyaluronate, Knee Osteoarthropathy, Curative Effect</p><disp-formula id="hanspub.37710-formula12"><graphic xlink:href="//html.hanspub.org/file/26-1571548x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/26-1571548x7_hanspub.png" /> <img src="//html.hanspub.org/file/26-1571548x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>膝骨关节病(Knee osteoarthrosis, KOA)是全球性的老年性致残性疾病，发病率高，早期表现为关节疼痛、活动受限，随着病程的进展，逐渐出现关节畸形、功能障碍等情况，严重影响患者生活质量，同时给家庭和社会带来了沉重的经济负担 [<xref ref-type="bibr" rid="hanspub.37710-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.37710-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37710-ref3">3</xref>]。我国的膝关节症状性骨性关节病患病率约8.1%，目前分为基础治疗、药物治疗、修复性治疗及重建治疗四个层次 [<xref ref-type="bibr" rid="hanspub.37710-ref4">4</xref>]。相比较于外用药物，口服药经过胃肠道吸收，可较快地达到较高的血药浓度，但对胃肠道的刺激性也相对较大，目前最常用于治疗KOA的是NSAID药物，首选选择性COX-2抑制剂，比如塞来昔布。近些年关于关节内透明质酸治疗膝关节骨性关节炎的报道日益增加 [<xref ref-type="bibr" rid="hanspub.37710-ref5">5</xref>]，玻璃酸钠可起到润滑关节，抑制免疫反应、保护关节软骨作用。非甾体类抗炎药、关节内皮质类固醇、富血小板血浆(PRP)和透明质酸钠等各种保守药物治疗方法层出不穷，但目前对于最佳方案尚未有明确结论，本文通过对口服塞来昔布、塞来昔布联合玻璃酸钠治疗KOA的疗效对比，探讨出更加有效的用药方案，现在报告如下。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>纳入标准：1) 符合OA诊断标准 [<xref ref-type="bibr" rid="hanspub.37710-ref6">6</xref>]；2) 近期未对膝骨关节病进行针对性治疗；3) BMI &lt; 35 kg/m<sup>2</sup>；4) 自愿接受治疗并有能力完成随访患者。</p><p>排除标准：1) 合并心脑血管及神经、精神系统疾病；2) 既往有磺胺类药物过敏或合并消化道相关疾病；3) 诊断为类风湿性关节炎、银屑病性关节炎等。</p><p>选取2019年1月至6月于我院接受保守治疗且符合标准的膝骨关节病患者100例，按照随机数法分为单纯口服塞来昔布组和塞来昔布联合玻璃酸钠组各50例，所有患者均签署知情同意书，本研究通过医院伦理委员会批准。</p></sec><sec id="s6_2"><title>2.2. 试验方法</title><p>塞来昔布组：200 mg/次，2次/日，连续口服8周为1疗程；联合组：在口服塞来昔布的基础上注射玻璃酸钠注射液(商品名：阿尔治) 2.5 ml/次，1次/周，连续注射5周为1疗程。注射方法：患者取坐位，双膝下垂，关节自然弯曲约至90˚，取髌腱外侧1 cm关节间隙处为进针点，碘酊消毒3次，酒精脱碘3次后铺单，用5 ml空针行关节腔穿刺，有突破感后停止进针，回抽无血说明进入关节腔，若有积液，尽可能抽取干净后注射玻璃酸钠2.5 ml，拔针后碘伏棉球消毒，敷贴粘贴进针点，协助患者活动膝关节数次，使玻璃酸钠均匀涂抹关节，嘱其在随访期间禁止接受其他治疗方案。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>记录患者基础治疗前年龄、性别、BMI等基本资料，随访并分析患者接受治疗后1个月、3个月及6个月的VAS疼痛评分、WOMAC评分 [<xref ref-type="bibr" rid="hanspub.37710-ref7">7</xref>] 及Lysholm评分 [<xref ref-type="bibr" rid="hanspub.37710-ref8">8</xref>]。VAS评分分为0~10分，由患者根据疼痛程度自行打分，分值越小代表疼痛越轻；WOMAC评分量表分为疼痛、僵硬、进行日常生活的难度三部分，每个答案从“没有困难”、“轻微”、“中等”、“非常”到“极端困难”，依次得分0~4分，得分相加即为总分，得分越小代表膝关节功能越好；Lysholm评分分为跛行、疼痛、交锁等8个方面，总分100分，95分以上为优秀，低于65分为差。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS 26.0软件行数据分析。对数据进行正态性检验，符合正态分布的计量资料用( x &#175; &#177; s )表示，组间比较：非正态分布的计量资料用非参数U检验；正态分布的计量资料组间比较用独立样本t检验，计数资料用卡方检验；检验水准(P)为0.05。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般资料</title><p>两组共100名患者均获得随访，其中塞来昔布组女性28例(56%)，男性22例，平均年龄(60.64 &#177; 6.11)岁，左膝关节26例(52%)，右膝关节24例，平均BMI为(27.39 &#177; 3.13) kg/m<sup>2</sup>，治疗前VAS评分平均为(5.38 &#177; 1.86)分，Lysholm评分为(45.24 &#177; 5.56)分，WOMAC评分为(54.00 &#177; 4.08)分；联合组女性29例(58%)，男性21例，平均年龄(58.24 &#177; 6.93)岁，左膝关节26例(52%)，右膝关节24例，平均BMI为(27.51 &#177; 2.73) kg/m<sup>2</sup>，治疗前VAS评分平均为(5.84 &#177; 1.63)分，Lysholm评分为(45.20 &#177; 6.05)分，WOMAC评分为(54.10 &#177; 2.82)分。两组患者治疗前所有指标差异均无统计学意义(P &gt; 0.05)，研究具有可行性。详见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic data of two groups before treatment (n = 50</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >塞来昔布组</th><th align="center" valign="middle" >联合组</th><th align="center" valign="middle" >U值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >性别(女，%)</td><td align="center" valign="middle" >28 (56)</td><td align="center" valign="middle" >29 (58)</td><td align="center" valign="middle" >0.041</td><td align="center" valign="middle" >0.840</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >60.64 &#177; 6.11</td><td align="center" valign="middle" >58.24 &#177; 6.93</td><td align="center" valign="middle" >969.000</td><td align="center" valign="middle" >0.052</td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >27.39 &#177; 3.13</td><td align="center" valign="middle" >27.51 &#177; 2.73</td><td align="center" valign="middle" >1157.500</td><td align="center" valign="middle" >0.524</td></tr><tr><td align="center" valign="middle" >VAS评分</td><td align="center" valign="middle" >5.38 &#177; 1.86</td><td align="center" valign="middle" >5.84 &#177; 1.63</td><td align="center" valign="middle" >1074.000</td><td align="center" valign="middle" >0.218</td></tr><tr><td align="center" valign="middle" >Lysholm评分</td><td align="center" valign="middle" >45.24 &#177; 5.56</td><td align="center" valign="middle" >45.20 &#177; 6.05</td><td align="center" valign="middle" >1245.000</td><td align="center" valign="middle" >0.972</td></tr><tr><td align="center" valign="middle" >WOMAC评分</td><td align="center" valign="middle" >54.00 &#177; 4.08</td><td align="center" valign="middle" >54.10 &#177; 2.82</td><td align="center" valign="middle" >1196.500</td><td align="center" valign="middle" >0.711</td></tr></tbody></table></table-wrap><p>表1. 两组患者治疗前基本资料(n = 50)</p></sec><sec id="s7_2"><title>3.2. 两组患者治疗后VAS评分</title><p>两组患者治疗后1个月、3个月及6个月VAS评分较治疗前均有明显降低(P &lt; 0.05)；治疗后1个月、3个月、6个月时联合组VAS评分均明显低于塞来昔布组(P &lt; 0.05)。详见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> VAS score of two groups of patients (n = 50</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >塞来昔布组</th><th align="center" valign="middle" >联合组</th><th align="center" valign="middle" >U值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >1个月</td><td align="center" valign="middle" >5.16 &#177; 0.79</td><td align="center" valign="middle" >4.08 &#177; 0.83</td><td align="center" valign="middle" >495.000</td><td align="center" valign="middle" >0.000*</td></tr><tr><td align="center" valign="middle" >3个月</td><td align="center" valign="middle" >4.14 &#177; 0.81</td><td align="center" valign="middle" >3.52 &#177; 1.11</td><td align="center" valign="middle" >849.000</td><td align="center" valign="middle" >0.004*</td></tr><tr><td align="center" valign="middle" >6个月</td><td align="center" valign="middle" >3.74 &#177; 1.21</td><td align="center" valign="middle" >2.46 &#177; 1.15</td><td align="center" valign="middle" >561.500</td><td align="center" valign="middle" >0.000*</td></tr></tbody></table></table-wrap><p>表2. 两组患者VAS评分(n = 50)</p><p>*表示两组差异有统计学意义(P &lt; 0.05)。</p></sec><sec id="s7_3"><title>3.3. 两组患者治疗后Lysholm评分</title><p>两组患者治疗后1个月、3个月及6个月VAS评分较治疗前均有明显降低(P &lt; 0.05)；治疗后1个月、3个月、6个月时联合组Lysholm评分均明显低于塞来昔布组(P &lt; 0.05)。详见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Lysholm score of two groups of patients (n = 50</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >塞来昔布组</th><th align="center" valign="middle" >联合组</th><th align="center" valign="middle" >U值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >1个月</td><td align="center" valign="middle" >60.04 &#177; 6.54</td><td align="center" valign="middle" >70.22 &#177; 5.79</td><td align="center" valign="middle" >321.500</td><td align="center" valign="middle" >0.000*</td></tr><tr><td align="center" valign="middle" >3个月</td><td align="center" valign="middle" >68.72 &#177; 5.61</td><td align="center" valign="middle" >78.98 &#177; 5.31</td><td align="center" valign="middle" >241.000</td><td align="center" valign="middle" >0.000*</td></tr><tr><td align="center" valign="middle" >6个月</td><td align="center" valign="middle" >75.30 &#177; 2.83</td><td align="center" valign="middle" >88.28 &#177; 4.88</td><td align="center" valign="middle" >275.000</td><td align="center" valign="middle" >0.000*</td></tr></tbody></table></table-wrap><p>表3. 两组患者Lysholm评分(n = 50)</p></sec><sec id="s7_4"><title>3.4. 两组患者治疗后WOMAC评分</title><p>两组患者治疗后1个月、3个月及6个月VAS评分较治疗前均有明显降低(P &lt; 0.05)；治疗后1个月、3个月时联合组WOMAC评分均明显低于塞来昔布组(P &lt; 0.05)，6个月时两组患者的WOMAC评分无明显差异(P &gt; 0.05)。详见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> WOMAC score of two groups of patients (n = 50</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >塞来昔布组</th><th align="center" valign="middle" >联合组</th><th align="center" valign="middle" >U值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >1个月</td><td align="center" valign="middle" >44.64 &#177; 3.15</td><td align="center" valign="middle" >38.34 &#177; 3.92</td><td align="center" valign="middle" >411.000</td><td align="center" valign="middle" >0.000*</td></tr><tr><td align="center" valign="middle" >3个月</td><td align="center" valign="middle" >35.10 &#177; 2.99</td><td align="center" valign="middle" >29.46 &#177; 2.57</td><td align="center" valign="middle" >223.000</td><td align="center" valign="middle" >0.000*</td></tr><tr><td align="center" valign="middle" >6个月</td><td align="center" valign="middle" >16.04 &#177; 2.10</td><td align="center" valign="middle" >15.70 &#177; 3.46</td><td align="center" valign="middle" >1007.500</td><td align="center" valign="middle" >0.093</td></tr></tbody></table></table-wrap><p>表4. 两组患者WOMAC评分(n = 50)</p></sec><sec id="s7_5"><title>3.5. 两组患者治疗后相关并发症</title><p>塞来昔布组患者随访期间未出现并发症，联合组1例患者注射玻璃酸钠后出现膝关节酸胀，疼痛加重，活动不便，休息辅助冰袋冷敷3天后症状消失。两组患者均未出现感染等严重并发症。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>膝骨关节病(KOA)是最常见的骨性关节病(osteoarthrosis)，其特征是关节软骨和软骨下骨的进行性损伤，在成年人中的患病率约为24%，且女性较男性更为常见 [<xref ref-type="bibr" rid="hanspub.37710-ref9">9</xref>]。临床最主要的表现是活动后加重，休息后缓解，随着疾病的进展，常伴有静息痛及晨僵，关节活动逐渐受限，影响日常生活 [<xref ref-type="bibr" rid="hanspub.37710-ref10">10</xref>]。目前分为基础治疗、药物治疗、修复性治疗及重建治疗四个层次，对于早中期及年龄小于65岁患者，优先考虑保守治疗。基础治疗包括预防保健和康复治疗两个方面，进行健康宣教，普及医学知识，建议患者进行科学的膝关节周围肌肉锻炼和适当的体育运动，并辅助中医及物理治疗。药物治疗可分为外用药物、口服药物、静脉用药及关节腔注射药物等几大类。口服药物可起到缓解关节疼痛，消炎消肿的作用，经过胃肠道消化吸收，虽可较快达到较高的血药浓度，但是副作用相对较大，NSAIDs类是最常用的口服药物，首选以塞来昔布等为代表的COX-2抑制剂。关节腔内注射粘多糖类药物如透明质酸钠具有润滑关节、保护软骨，减缓疾病进展的功能。</p><p>2013年美国骨科医师学会(AAOS)强烈推荐NSAIDs类药物用于治疗有症状的KOA，在骨关节炎的诊疗指南中，也推荐NSAIDs药物作为一线用药，其治疗效果也得到证实 [<xref ref-type="bibr" rid="hanspub.37710-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.37710-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.37710-ref13">13</xref>]。WOMAC评分通过疼痛、僵硬及对日常生活的影响三个方面评估膝关节功能 [<xref ref-type="bibr" rid="hanspub.37710-ref7">7</xref>]，Lysholm评分有较高的特异性和敏感度，可有效的反应膝关节局部功能 [<xref ref-type="bibr" rid="hanspub.37710-ref8">8</xref>]，VAS评分是运用最为广泛的疼痛评估量表 [<xref ref-type="bibr" rid="hanspub.37710-ref14">14</xref>]。在本研究中，单纯口服塞来昔布的患者在接受治疗后1个月、3个月及6个月的WOMAC评分、Lysholm评分及VAS评分较前均由明显改善，说明其具有良好的缓解疼痛，改善膝关节功能的作用，但随着时间的延长，效果逐渐不明显，说明塞来昔布等NSAIDs类药物可在短期内明显缓解症状，但无法长期维持功效。但在长达6个月的随访过程中，未发现患者出现相关并发症，说明塞来昔布具有较高的安全性，可以作为镇痛药，长期服用。有文献报道，COX-2选择性抑制剂对OA疾病改善是通过PG、细胞因子、MMPs和组织调节介导的，塞来昔布可通过体内和体外途径保护软骨、预防滑膜增生、抑制骨破坏从而可潜在得减缓OA进展 [<xref ref-type="bibr" rid="hanspub.37710-ref15">15</xref>]。</p><p>透明质酸(HA)作为粘多糖的一种是关节滑液和软骨基质的重要部分，在KOA患者关节液中透明质酸浓度和分子量均下降，文献报道，中分子量的透明质酸每周注射3次治疗KOA6个月以上的效果优于低分子量的透明质酸，且安全性相似 [<xref ref-type="bibr" rid="hanspub.37710-ref16">16</xref>]。因此在临床中通过给病人注射补充膝关节腔内高浓度透明质酸可提高关节液的浓度和弹性，更好的起到润滑作用，降低膝关节疼痛。同时，透明质酸是关节滑液的主要流体动力学非蛋白成分，其独特的粘弹性赋予关节液显著的减震和润滑能力，其巨大的大分子尺寸和亲水性可在关节连接过程中将液体保留在关节腔内。HA可以限制大的血浆蛋白和细胞进入关节液，但促进滑膜毛细血管和软骨及其他关节组织之间的物质交换。此外，HA可以在细胞周围形成一层细胞外衣，与促炎介质相互作用，并与细胞受体结合，调节细胞的增殖、迁移和基因表达。所有的物理化学和生物学特征均被证明与HA分子量有关 [<xref ref-type="bibr" rid="hanspub.37710-ref17">17</xref>]。透明质酸钠起效慢，作用时间长，在一项长达40个月的研究发现，比起安慰剂，接受HA可有效缓解患者KOA症状。在本研究中，联合组患者治疗后6个月，VAS评分和Lysholom评分均明显优于单纯口服塞来昔布患者，说明两者具有协同作用，且疗效持续时间更长。在随访期间，接受玻璃酸钠注射的患者未出现严重相关并发症，说明在严格遵守无菌操作原则的前提下，玻璃酸钠也是安全有效的。</p><p>在该研究中有几点需要注意，一是，关节腔穿刺属于有创操作并且直通关节腔，必须严格按照无菌原则操作，避免引起关节腔感染；二是，塞来昔布类药物虽是选择性COX-2抑制剂，对胃肠道刺激较小，且在本实验中未出现消化道相关并发症，但在研究中仍要严格把握纳入排除标准，避免不良事件的发生。本研究仍存在不足之处，首先是样本量较小，得出的结论需要在进一步更大样本量的研究中得到验证；二是随访时间短，停止治疗以后的后续效果是下一步研究的重点。</p></sec><sec id="s9"><title>5. 结论</title><p>总之，单纯口服塞来昔布、塞来昔布联合玻璃酸钠均可有效缓解KOA患者膝关节疼痛，但联合组效果更加明显，两者之间互相促进，相辅相成，从不同的角度共同治疗KOA，在缓解症状，提高生活质量方面更具有优势，因此值得临床推广。</p></sec><sec id="s10"><title>文章引用</title><p>赵 旋,史为鹏,杨 斌,徐奎帅,沈 瑞. 塞来昔布联合玻璃酸钠治疗膝骨关节病疗效探究The Effect of Celecoxib Combined with Sodium Hyaluronate in the Treatment of Knee Osteoarthropathy[J]. 临床医学进展, 2020, 10(09): 2042-2047. https://doi.org/10.12677/ACM.2020.109306</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37710-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">吴锋, 叶劲, 翁永前, 陈伟明, 陈玉书, 白波. 艾瑞昔布联合玻璃酸钠治疗膝骨关节炎的早期疗效分析[J]. 中华骨与关节外科杂志, 2019, 12(12): 973-977.</mixed-citation></ref><ref id="hanspub.37710-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Meiyappan, K.P., Cote, M.P., Bozic, K.J., et al. (2020) Adherence to the American Academy of Orthopaedic Surgeons Clinical Practice Guidelines for Nonoperative Management of Knee Osteoarthritis. Journal of Arthroplasty, 35, 347-352. &lt;br&gt;https://doi.org/10.1016/j.arth.2019.08.051</mixed-citation></ref><ref id="hanspub.37710-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Trojian, T.H., Concoff, A.L., Joy, S.M., et al. (2016) AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis: Importance for Individual Patient Outcomes. Clinical Journal of Sport Medicine, 26, 1-11.  
&lt;br&gt;https://doi.org/10.1097/JSM.0000000000000274</mixed-citation></ref><ref id="hanspub.37710-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">王波, 余楠生. 膝骨关节炎阶梯治疗专家共识(2018年版)[J]. 中华关节外科杂志(电子版), 2019, 13(1): 124-130.</mixed-citation></ref><ref id="hanspub.37710-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Xing, D., Wang, B., Liu, Q., et al. (2016) Intra-Articular Hyaluronic Acid in Treating Knee Osteoarthritis: A PRISMA-Compliant Systematic Review of Overlapping Meta-Analysis. Scientific Reports, 6, Article No. 32790.  
&lt;br&gt;https://doi.org/10.1038/srep32790</mixed-citation></ref><ref id="hanspub.37710-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会骨科分会关节外科学组, 吴阶平医学基金会骨科学专家委员会. 膝骨关节炎阶梯治疗专家共识(2018年版)[J]. 中华关节外科杂志(电子版), 2019, 13(1): 124-130.</mixed-citation></ref><ref id="hanspub.37710-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ackerman, I.N., Tacey, M.A., Ademi, Z., et al. (2014) Using WOMAC Index Scores and Personal Characteristics to Estimate Assessment of Quality of Life Utility Scores in People with Hip and Knee Joint Disease. Quality of Life Research, 23, 2365-2374. &lt;br&gt;https://doi.org/10.1007/s11136-014-0667-y</mixed-citation></ref><ref id="hanspub.37710-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ted, S., Gen, E. and Toru, Y. (2018) Correlation between Single Assessment Numerical Evaluation Score and Lysholm Score in Primary Total Knee Arthroplasty Patients. Arthroplast Today, 4, 99-102.  
&lt;br&gt;https://doi.org/10.1016/j.artd.2017.09.004</mixed-citation></ref><ref id="hanspub.37710-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Pereira, D., Peleteiro, B., Araujo, J., et al. (2011) The Effect of Osteoarthritis Definition on Prevalence and Incidence Estimates: A Systematic Review. Osteoarthritis and Cartilage, 19, 1270-1285.  
&lt;br&gt;https://doi.org/10.1016/j.joca.2011.08.009</mixed-citation></ref><ref id="hanspub.37710-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bijlsma, J.W.J., et al. (2011) Osteoarthritis: An Update with Relevance for Clinical Practice. The Lancet, 377, 2115-2126. &lt;br&gt;https://doi.org/10.1016/S0140-6736(11)60243-2</mixed-citation></ref><ref id="hanspub.37710-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">粟迎春, 雷小俊. 关节腔内注射透明质酸钠联合塞来昔布治疗早中期膝关节骨关节炎的疗效分析[J]. 中华关节外科杂志(电子版), 2017, 11(2): 204-208.</mixed-citation></ref><ref id="hanspub.37710-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">徐东, 张奉春, 古洁若, 徐建华, 陶怡, 张凤肖, 何培根, 鲍春德, 肖卫国. 艾瑞昔布治疗膝骨关节炎的Ⅲ期多中心随机双盲临床试验[J]. 中华临床免疫和变态反应杂志, 2014, 8(3): 205-210.</mixed-citation></ref><ref id="hanspub.37710-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">顾新丰, 何杰, 张琥, 郑昱新. 透明质酸钠治疗膝骨关节炎的疗效及其影响因素分析[J]. 中华关节外科杂志(电子版), 2016, 10(3): 255-259.</mixed-citation></ref><ref id="hanspub.37710-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Tracy, F., Sarah, H., John, K., et al. (2013) Different Wording of the Patient Global Visual Analogue Scale (PG-VAS) Affects Rheumatoid Arthritis Patients’ Scoring and the Overall Disease Activity Score (DAS28): A Cross-Sectional Study. Musculoskeletal Care, 11, 229-237. &lt;br&gt;https://doi.org/10.1002/msc.1046</mixed-citation></ref><ref id="hanspub.37710-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">郑志远, 卑明健, 张柳. COX-2选择性抑制剂在骨关节炎中作用的研究进展[J]. 中国煤炭工业医学杂志, 2019, 22(2): 182-186.</mixed-citation></ref><ref id="hanspub.37710-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Francis, B., Joachim, G., Sara, C., et al. (2012) A Randomised, Double-Blind, Controlled Trial Comparing Two Intra-Articular Hyaluronic Acid Preparations Differing by Their Molecular Weight in Symptomatic Knee Osteoarthritis. Annals of the Rheumatic Diseases, 71, 1454-1460. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2011-200972</mixed-citation></ref><ref id="hanspub.37710-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ghosh, P. and Guidolin, D. (2002) Potential Mechanism of Action of Intra-Articular Hyaluronan Therapy in Osteoarthritis: Are the Effects Molecular Weight Dependent? Seminars in Arthritis and Rheumatism, 32, 10-37.  
&lt;br&gt;https://doi.org/10.1053/sarh.2002.33720</mixed-citation></ref></ref-list></back></article>